TABLE 1

Follow-up of 9 Patients with 18F-FDG–Avid Bone Lesions 3 Months After Therapy

Patient no.Decrease in SUVmax (%)*VEGF response†
188.3CR
266.4CR
359.0PR
470.9CR
578.7CR
681.5CR
750.3CR
870.2PR
997.3CR

  • ↵* Decrease in SUVmax (%) was calculated using average percentage of decrease for every 18F-FDG–avid lesion in 1 person.

  • ↵† VEGF response; CR, normalized VEGF (<600 pg/mL); PR, VEGF improved by at least 50%.

  • CR = complete response; PR = partial response.